Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Active, not recruiting · NCT03038672 · Registry updated 2026-05-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | ALK-positive large B-cell lymphoma, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, diffuse large B-cell lymphoma of the central nervous system, immune system disorder, immunoproliferative disorder, intravascular large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphomatoid granulomatosis, lymphoproliferative syndrome, neoplasm, plasmablastic lymphoma, precancerous condition, primary effusion lymphoma, viral infectious disease | Active, not recruiting | Phase 2 | 2026-05-12 | NCT03038672 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
33 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.